| 1. |
- Gidlöf, Olof, et al.
(författare)
-
MicroRNAs in the failing heart - Novel therapeutic targets?
- 2014
-
Ingår i: Scandinavian Cardiovascular Journal. - : Informa UK Limited. - 1651-2006 .- 1401-7431. ; 48:6, s. 328-334
-
Forskningsöversikt (refereegranskat)abstract
- Abstract Heart failure is a common and disabling disease with high mortality that carries substantial societal costs. Current therapeutic strategies are aimed at relieving symptoms, avoiding hospitalization, and prolonging life, but disease progression is ultimately inevitable. MicroRNAs (miRNAs) are short, non-coding RNA molecules with pervasive roles in eukaryotic biology, annealing to complimentary sites on target mRNAs, and repressing gene expression. The fact that miRNAs are dysregulated in many human disorders, including cardiovascular disease, and the relative ease with which endogenous miRNA expression can be altered using synthetic antisense oligos has stirred enthusiasm for these molecules as potential drug targets. The aim of this review article was to summarize the current knowledge on the roles of miRNA in the pathophysiology of heart failure as well as the use of miRNAs as therapeutic targets and diagnostic tools for the disease.
|
|
| 2. |
- Gidlöf, Olof
(författare)
-
Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure
- 2021
-
Ingår i: Frontiers in Physiology. - : Frontiers Media SA. - 1664-042X. ; 12
-
Forskningsöversikt (refereegranskat)abstract
- The natriuretic peptide system (NPS) plays a fundamental role in maintaining cardiorenal homeostasis, and its potent filling pressure-regulated diuretic and vasodilatory effects constitute a beneficial compensatory mechanism in heart failure (HF). Leveraging the NPS for therapeutic benefit in HF has been the subject of intense investigation during the last three decades and has ultimately reached widespread clinical use in the form of angiotensin receptor-neprilysin inhibition (ARNi). NPS enhancement via ARNi confers beneficial effects on mortality and hospitalization in HF, but inhibition of neprilysin leads to the accumulation of a number of other vasoactive peptides in the circulation, often resulting in hypotension and raising potential concerns over long-term adverse effects. Moreover, ARNi is less effective in the large group of HF patients with preserved ejection fraction. Alternative approaches for therapeutic augmentation of the NPS with increased specificity and efficacy are therefore warranted, and are now becoming feasible particularly with recent development of RNA therapeutics. In this review, the current state-of-the-art in terms of experimental and clinical strategies for NPS augmentation and their implementation will be reviewed and discussed.
|
|
